Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Zurich | OTHER |
| University Hospital, Zürich | OTHER |
Not provided
Not provided
Not provided
Not provided
The Global Healthcare Study on Psoriasis (GHSP) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with psoriasis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.
The study employs a combined retrospective and prospective design, collecting data from routine clinical care and medical records spanning from January 2020 through the study conclusion.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Global Healthcare Study on Psoriasis | Patients with Psoriasis |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Psoriasis Area Severity Index (PASI) | Composite clinician-assessed measure of psoriasis severity based on erythema, scaling, thickness, and affected body surface area; total score ranges from 0 to 72, with higher scores indicating more severe disease. | Baseline and follow-up visits every 6-12 months for up to 5 years. |
| Measure | Description | Time Frame |
|---|---|---|
| Dermatology Life Quality Index (DLQI) | Patient-reported measure of dermatology-specific quality of life; total score ranges from 0 to 30, with higher scores indicating greater impairment. | Baseline and follow-up visits every 6-12 months for up to 5 years. |
| Nail Psoriasis Severity Index (NAPSI) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patient populations across world regions seen for psoriasis.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Julia-Tatjana Maul | Contact | +41 76 441 51 09 | julia-tatjana.maul@uzh.ch | |
| Johannes A Didaskalu, Prof. Dr. med. | Contact | +41 76 36 19 475 | johannes.didaskalu@uzh.ch |
| Name | Affiliation | Role |
|---|---|---|
| Julia-Tatjana Maul, Prof. Dr. med. | University of Zurich | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Zurich | Recruiting | Zurich | Switzerland |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38470165 | Result | Maul JT, Maul LV, Didaskalu JA, Valenzuela F, Romiti R, Peterson H, Korouri E, Novoa F, Oon HH, Zheng M, Wu JJ, Thyssen JP, Egeberg A, Armstrong AW, Nielsen ML. Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on Psoriasis. Acta Derm Venereol. 2024 Mar 12;104:adv20329. doi: 10.2340/actadv.v104.20329. | |
| 35988043 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011565 | Psoriasis |
| ID | Term |
|---|---|
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Clinician-assessed measure of nail psoriasis severity based on nail matrix and nail bed involvement; scores range from 0-80 for fingernails and 0-80 for toenails; total score ranges from 0-160, with higher scores indicating more severe nail disease. |
| Baseline and follow-up visits every 6-12 months for up to 5 years. |
| Numerical Rating Scale (NRS) for disease severity | Patient-reported assessment of psoriasis severity on a numerical rating scale from 0 (no disease) to 10 (most severe disease imaginable). | Baseline and follow-up visits every 6-12 months for up to 5 years. |
| Physician Global Assessment (PGA) | Clinician-assessed global measure of psoriasis severity on a scale from 0 (clear) to 4 (severe). | Baseline and follow-up visits every 6-12 months for up to 5 years. |
| Body Surface Area (BSA) | Percentage of total body surface area affected by psoriasis, ranging from 0% to 100%. | Baseline and follow-up visits every 6-12 months for up to 5 years. |
| Result |
| Valenzuela F, De La Cruz C, Lecaros C, Fernandez J, Hevia G, Maul LV, Thyssen JP, Vera-Kellet C, Egeberg A, Armijo D, Pizarro C, Riveros T, Correa H, Guglielmetti A, Didaskalu JA, Wu JJ, Griffiths CEM, Romiti R, Maul JT. Comorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis. Clin Exp Dermatol. 2022 Dec;47(12):2234-2241. doi: 10.1111/ced.15384. Epub 2022 Oct 28. |
| 36653920 | Result | Maul JT, Frohlich F, Maul LV, Stunnenberg R, Valenzuela F, De La Cruz C, Vera-Kellet C, Armijo D, Cesar WG, Carvalho A, Didaskalu JA, Graf N, Egeberg A, Wu JJ, Thyssen JP, Romiti R, Griffiths CEM. Access to psoriasis treatment in Brazil and Chile: A cross-sectional multicentre Global Healthcare Study on Psoriasis. Br J Dermatol. 2023 Mar 30;188(4):533-541. doi: 10.1093/bjd/ljac128. |
| 39459597 | Result | Korouri E, Jeong C, Peterson H, Valenzuela F, Romiti R, Didaskalu JA, Egeberg A, Oon HH, Maul LV, Kingston P, Lee K, Huang MY, Yee D, Artiga K, Aguero R, Maul JT, Armstrong AW. Global Comparison of COVID-19 Vaccination Rates among Psoriasis Patients. Life (Basel). 2024 Oct 13;14(10):1297. doi: 10.3390/life14101297. |
| 41319042 | Result | Goh E, Nielsen ML, Maul LV, Didaskalu JA, Chularojanamontri L, Guevara BEK, Ji M, Zheng M, Maul JT, Oon HH. Clinical Characteristics and Treatment Patterns of Psoriasis in Asia and Switzerland: Results of the Multicentre Global Healthcare Study on Psoriasis (GHSP). Int J Dermatol. 2026 Jun;65(6):1195-1202. doi: 10.1111/ijd.70183. Epub 2025 Nov 30. |